Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway
The Journal of Pharmacology and Experimental Therapeutics · 2024-10 · 391 (1) · 91-103
DOI: 10.1124/jpet.124.002302 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-10. Verfasst von Jim Zheng und 19 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R…. Hauptthemen laut MEDLINE: Rats, Sprague-Dawley. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few Food and Drug Administration-approved drugs that exhibit atropisomerism. LEN exists as a mixture of two class 2 atropisomers that interconvert at a fast rate (half-life < 2 hours) with a ratio that is stable over time and unaffected by enzymes or binding to proteins in plasma. LEN exhibits low systemic clearance (CL) in nonclinical species and humans; however, in all species, the observed CL was higher than the in vitro predicted CL. The volume of distribution was moderate in nonclinical species and consistent with the tissue distribution observed by whole-body autoradiography in rats. LEN does not distribute to brain, consistent with being a P-glycoprotein (P-gp) substrate. Mechanistic drug disposition studies with [14C]LEN in intravenously dosed bile duct-cannulated rats and dogs showed a substantial amount of unchanged LEN (31%-60% of dose) excreted in feces, indicating that intestinal excretion (IE) was a major clearance pathway for LEN in both species. Coadministration of oral elacridar, a P-gp inhibitor, in rats decreased CL and IE of LEN. Renal excretion was < 1% of dose in both species. In plasma, almost all radioactivity was unchanged LEN. Low levels of metabolites in excreta included LEN conjugates with glutathione, pentose, and glucuronic acid, which were consistent with metabolites formed in vitro in Hμrel hepatocyte cocultures and those observed in human. Our studies highlight the importance of IE for efflux substrates that are highly metabolically stable compounds with slow elimination rates. SIGNIFICANCE STATEMENT: LEN is a long-acting injectable that exists as conformationally stable atropisomers. Due to an atropisomeric interconversion rate that significantly exceeds the in vivo elimination rate, the atropisomer ratio of LEN remains constant in circulation. The disposition of LEN highlights that intestinal excretion has a substantial part in the elimination of compounds that are metabolically highly stable and efflux transporter substrates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Mad…
ORCID-Profile: Jim Zheng, Raju Subramanian
Zitieren
APA
Zheng, J., Lu, B., Carr, G., Mwangi, J., Wang, K., Hao, J., Staiger, K. M., Kozon, N., Murray, B. P., Bashir, M., Gohdes, M. A., Tse, W. C., Schroeder, S., Graupe, M., Link, J. O., Yoon, J., Chiu, A., Rowe, W., Smith, B. J., & Subramanian, R. (2024). Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway. The Journal of Pharmacology and Experimental Therapeutics, 391(1), 91-103. https://doi.org/10.1124/jpet.124.002302
Vancouver
Zheng J, Lu B, Carr G, Mwangi J, Wang K, Hao J, et al. Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway. The Journal of Pharmacology and Experimental Therapeutics. 2024;391(1):91-103. doi:10.1124/jpet.124.002302
BibTeX
@article{Zheng2024,
author = {Zheng, Jim and Lu, Bing and Carr, Gavin and Mwangi, Judy and Wang, Kelly and Hao, Jia and Staiger, Kelly McLennan and Kozon, Nathan and Murray, Bernard P and Bashir, Mohammad and Gohdes, Mark A and Tse, Winston C and Schroeder, Scott and Graupe, Michael and Link, John O and Yoon, Jungjoo and Chiu, Anna and Rowe, William and Smith, Bill J and Subramanian, Raju},
title = {Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2024},
volume = {391},
number = {1},
pages = {91--103},
doi = {10.1124/jpet.124.002302}
}
EUVIMED